Skip to main content

CSL COVID19 Update

CSL continues to provide medicines to patients around the world.

coronavirus on a blue background

Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. In addition, we have taken measures to support the health and well-being of our people. We continue to closely monitor the outbreak to minimize business impact. (CSL is the parent company of CSL Behring and Seqirus)

Our People:

We have taken numerous steps to help ensure the health and safety of our workforce. This includes restricting international travel through 1 July 2021, postponing large group meetings, and encouraging employees to leverage various communication technologies to minimize business disruption.

Our Efforts:

CSL and AstraZeneca have agreed for CSL to manufacture approximately 50 million doses of Vaccine AstraZeneca in Australia for supply to the country. First doses were rolled out in March 2021.

CSL Behring has launched a clinical trial into the use of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia. A Phase 2 study to assess the safety and efficacy of the potential treatment has completed enrollment and results are expected in the second quarter of 2021.

In addition, CSL continues to evaluate additional assets in its portfolio and partnerships with external researchers for potential use in the fight against COVID-19.

These are just some of CSL’s many efforts to combat the global pandemic. To see what else we are doing, please see our Fact Sheet.

Our Patients & Products:

CSL continues to provide an uninterrupted supply of our medicines around the world. As the COVID-19 situation evolves, we are closely tracking any impact it could have on our operations.

We have ongoing clinical trials at investigational sites worldwide and remain in close contact with researchers who are involved in this important work to evaluate promising new medicines, discussing the best ways to manage patient visits and follow-up appointments.

Our Donors:

Our plasma collection network is operational. Our plasma centers are committed to the highest standards of quality and safety for our employees and donors.